---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-219377"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2026-05-12T20:05:31+00:00"
generated_at: "2026-05-12T21:33:21.410489+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kyverna reports Q1 net loss $39.7M; initiates rolling BLA for miv-cel in SPS

## Summary
- Cash, cash equivalents and marketable securities of $236.4M as of March 31, 2026; cash runway expected into 2028.
- Net loss of $39.7M ($0.66 per share) for Q1 2026; R&D expenses $30.1M, G&A $11.3M.
- Initiated rolling BLA submission for miv-cel in stiff person syndrome after positive pre-BLA meeting with FDA; completion expected Q4 2026.
- Primary analysis of KYSA-8 trial in SPS showed statistically significant durable benefit across all endpoints; 100% of patients free of immunotherapies at week 16.
- Appointed Nadia Dac as Chief Commercial Officer; enrollment ongoing in Phase 3 gMG trial.

## SEC filing metadata
- accession: 0001193125-26-219377
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2026-05-12T20:05:31+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000119312526219377/0001193125-26-219377-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000119312526219377/kytx-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-219377
- JSON: https://secwatch.observer/filing/0001193125-26-219377.json
- Plain text: https://secwatch.observer/filing/0001193125-26-219377.txt

## Key facts
- Earnings Releases
  Kyverna Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.
  - Period: first quarter ended March 31, 2026
  - Result: reported results
  source text: On May 12, 2026, Kyverna Therapeutics, Inc. (the “Company”) issued a press release providing a business update and reporting financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1994702/000119312526219377/0001193125-26-219377-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.